Literature DB >> 17633027

Targeting TRAfs for therapeutic intervention.

Juan M Zapata1, Sophie Lefebvre, John C Reed.   

Abstract

TNF-receptor associated factors (TRAFs) are the molecules that upon engagement of the TNF-receptor (TNFR) by a TNF-family ligand come first in contact with the activated TNFR, initially acting as docking molecules for kinases and other effector proteins that are recruited to the activated receptor. TRAFs later regulate the subcellular relocalization of the receptor-ligand complex and finally they modulate the extent of the response by controlling the degradation of key proteins in the pathway. In this chapter, we review the involvement of different TRAF family members in the etiology of a variety of pathologies and address the question of whether the use of TNFR-mimic-peptides or small molecule modulators targeting TRAFs might be suitable for therapeutic intervention, discussing the advantages and disadvantages of this strategy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17633027     DOI: 10.1007/978-0-387-70630-6_15

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  17 in total

1.  Comparison of the peptide binding preferences of three closely related TRAF paralogs: TRAF2, TRAF3, and TRAF5.

Authors:  Glenna Wink Foight; Amy E Keating
Journal:  Protein Sci       Date:  2016-02-03       Impact factor: 6.725

Review 2.  TWEAK and TRAF6 regulate skeletal muscle atrophy.

Authors:  Ashok Kumar; Shephali Bhatnagar; Pradyut K Paul
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2012-05       Impact factor: 4.294

3.  TNF receptor-associated factor 6 in advanced non-small cell lung cancer: clinical and prognostic implications.

Authors:  Hui Liu; Tiantuo Zhang; Jin Ye; Hongtao Li; Jing Huang; Xiaodong Li; Benquan Wu; Xubing Huang; Jinghui Hou
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-27       Impact factor: 4.553

4.  Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation.

Authors:  Chao Zheng; Venkataraman Kabaleeswaran; Yaya Wang; Genhong Cheng; Hao Wu
Journal:  Mol Cell       Date:  2010-04-09       Impact factor: 17.970

5.  Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB).

Authors:  Arantza Azpilikueta; Elixabet Bolaños; Valerie Lang; Sara Labiano; Maria A Aznar; Iñaki Etxeberria; Alvaro Teijeira; Maria E Rodriguez-Ruiz; Jose L Perez-Gracia; Maria Jure-Kunkel; Juan M Zapata; Manuel S Rodriguez; Ignacio Melero
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

6.  TNFR-associated factor 2 deficiency in B lymphocytes predisposes to chronic lymphocytic leukemia/small lymphocytic lymphoma in mice.

Authors:  Gema Pérez-Chacón; David Llobet; Constanza Pardo; José Pindado; Yongwon Choi; John C Reed; Juan M Zapata
Journal:  J Immunol       Date:  2012-06-18       Impact factor: 5.422

7.  Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer.

Authors:  Juan M Zapata; David Llobet; Maryla Krajewska; Sophie Lefebvre; Christina L Kress; John C Reed
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

8.  Constitutive production of NF-kappaB2 p52 is not tumorigenic but predisposes mice to inflammatory autoimmune disease by repressing Bim expression.

Authors:  Zhe Wang; Baochun Zhang; Liqun Yang; Jane Ding; Han-Fei Ding
Journal:  J Biol Chem       Date:  2008-02-15       Impact factor: 5.157

9.  Distinct roles of TRAF6 at early and late stages of muscle pathology in the mdx model of Duchenne muscular dystrophy.

Authors:  Sajedah M Hindi; Shuichi Sato; Yongwon Choi; Ashok Kumar
Journal:  Hum Mol Genet       Date:  2013-10-24       Impact factor: 6.150

Review 10.  Structural feature of TRAFs, their related human diseases and therapeutic intervention.

Authors:  Hyun Ho Park
Journal:  Arch Pharm Res       Date:  2021-05-10       Impact factor: 4.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.